CPC A61K 35/17 (2013.01) [A61K 39/12 (2013.01); A61K 39/235 (2013.01); A61K 39/245 (2013.01); C12M 23/24 (2013.01); C12N 5/0636 (2013.01); C12N 7/00 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/55527 (2013.01); C12N 2501/2304 (2013.01); C12N 2501/2307 (2013.01); C12N 2506/11 (2013.01); C12N 2710/10034 (2013.01); C12N 2710/16134 (2013.01); C12N 2710/18034 (2013.01); Y02A 50/30 (2018.01)] | 28 Claims |
1. An in vitro expansion process for rapid of antigen specific T cells, comprising culturing in a vessel comprising a gas permeable culture surface a population of PBMCs in a culture in the presence of an antigen, wherein the antigen is in the form of a peptide or a peptide mix relevant to a target antigen(s) and wherein the antigen is added to the culture in the range of from 1 to 500 ng per ml; wherein the culturing is performed in the presence of an exogenous cytokine wherein the cytokine is other than exogenous IL-2 and is selected from the group comprising IL-1, IL-4, IL-6, IL-7, IL-12, IL-15 and combinations thereof; wherein antigens, cytokines, media and nutrients are not added or changed after initiation of the expansion process; wherein the expansion to provide the desired population of T cells is 20 days or less; wherein the desired population of cells is a CD56− population; and wherein the peptide or peptide mix is/are not added to the culture presented on dendritic cells.
|